The naphtha catalytic reforming process is evaluated by designing new composite nano-catalysts. Three catalysts were prepared for this process. The first catalyst was molybdenum carbide composite with platinum over HY zeolite (Mo2C.Pt/HY zeolite), the second catalyst was molybdenum carbide composite with platinum over modified zeolite by cerium nitrate (Mo2C.Pt/CeY zeolite), and the last catalyst was bimetallic titanium and platinum with a titanium content of 1% and platinum content of 0.11% over HY zeolite (Pt.Ti/HY zeolite). All catalysts were tested with several tests, mainly X-Ray Diffraction (XRD), BET surface area, and pore volume. All these substances were applied as catalysts for the reforming process of Iraqi heavy naphtha at the following operating conditions: reaction temperature (480, 500, and 520 ), reaction pressure (10, 12.5, and 15 bar), liquid hourly space velocity (LHSV) at 2 hr-1, and constant hydrogen to hydrocarbon ratio (H2/ HC) of 4. All the reforming reactions occurred in a packed bed pilot plant reactor to investigate its stability and activity during the reforming process. All the developed catalyst samples showed sensational stability even at operating under difficult circumstances. The best catalyst was Pt.Ti/HY zeolite based on the results obtained with respect to the octane number (86.2) at 520  and 15 bar. Also, a mathematical model to describe the reforming process with high accuracy was built and simulated using gPROMS software. The results were very satisfying since the most significant error with the wt% of reformate was 4.9% (the experimental aromatics content was 23.94 wt.%, while the predicted result was 21.67 wt.%), while Research Octane Number (RON) error was 4.7% (the experimental RON was 81, whereas the predicted value of RON was 85) among all the results meaning that the simulating was valid to describe the process.

Backgroundand Objectives: Bladder cancer is considered a major problem world wide. Aberrant P 53 , mutant vascular endothelial growth factor and deregulated expression of survivin were used as biochemical markers for investigation, prognosis and follow up. Aims: This study was conducted to assess the prognostic impact of altered expressions of these parameters in Erbil population with bladder cancer and correlated with other confounding factors age, gender and smoking effects, these factors also correlated with histopathologic characteristics such as grade and stage. Patients and Methods: This prospective study enrolled 50 newly diagnosed patients with bladder cancer, in addition 50 apparently healthy adults age-sex matched were also involved in this study. Serum parameters levels were measured using enzyme linked immunosorbent assay. Patients had these general criteria, newly discovered cases, no deep x-ray therapy, no chemotherapy, no hormonal therapy with histologic and cytologic confirmation of bladder cancer. Statistical Study: Data were analyzed using SPSS v. 18. Results: The mean serum P 53 ,vascular endothelial growth factor and survivin levels in patient and control groups were P 53 = 1.682 ±0.665, 1.192 ± 0.284, vascular endothelial growth factor = 5.296 ±2.8, 2.000 ±0.704 and survivin = 5.468±0.715, 4.240±0.656 respectively. The statistical analysis revealed that, serum parameters levels were significantly increased in patients as compared with control group p< 0.001. Conclusion: Data revealed for the first time the relation between altered expressions of interested parameters in combination pattern with the incidence of bladder cancer in Erbil population, which has not previously reported in this region.This study tested the hypothesis and supported the concept that higher serum levels of these parameters might be a pathogenic and prognostic factors and a markers of tumor aggressiveness in bladder cancer. Early diagnosis is necessary for maximizing the rate of therapy. The gold standard care for the investigating of bladder cancer is cystoscopy which detects tumors accurately but it is invasive, expensive, and represents a high burden to the patients, and also, small papillary and flatgrowing cancer may be missed. Regular cystoscopic examinations performed for monitoring the patients, because the recurrent rate is high. Therefore, this study was conducted to investigate the possibilities for replacing cystoscopy with more accurate, safe, no expensive, noninvasive diagnostic test and to recognize a new approach for providing opportunities for early detection which is an important goal to speed up the therapy of patients.